268 related articles for article (PubMed ID: 29406263)
1. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
Agrahari V; Agrahari V
Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
[TBL] [Abstract][Full Text] [Related]
2. Characterization of nanomedicines: A reflection on a field under construction needed for clinical translation success.
Coty JB; Vauthier C
J Control Release; 2018 Apr; 275():254-268. PubMed ID: 29454063
[TBL] [Abstract][Full Text] [Related]
3. Challenges associated and approaches for successful translation of nanomedicines into commercial products.
Agrahari V; Hiremath P
Nanomedicine (Lond); 2017 Apr; 12(8):819-823. PubMed ID: 28338401
[No Abstract] [Full Text] [Related]
4. Current hurdles to the translation of nanomedicines from bench to the clinic.
Đorđević S; Gonzalez MM; Conejos-Sánchez I; Carreira B; Pozzi S; Acúrcio RC; Satchi-Fainaro R; Florindo HF; Vicent MJ
Drug Deliv Transl Res; 2022 Mar; 12(3):500-525. PubMed ID: 34302274
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
Dri DA; Rinaldi F; Carafa M; Marianecci C
Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
[TBL] [Abstract][Full Text] [Related]
7. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
[TBL] [Abstract][Full Text] [Related]
8. Updated Regulatory Considerations for Nanomedicines.
Subin TS; Vijayan V; Kumar KJR
Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
[TBL] [Abstract][Full Text] [Related]
9. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
[TBL] [Abstract][Full Text] [Related]
10. The nanomedicines alliance: an industry perspective on nanomedicines.
Malinoski FJ
Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
[TBL] [Abstract][Full Text] [Related]
11. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
Urbán P; Liptrott NJ; Bremer S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649
[TBL] [Abstract][Full Text] [Related]
12. An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market.
Kad A; Pundir A; Arya SK; Bhardwaj N; Khatri M
J Pharm Innov; 2022; 17(1):249-265. PubMed ID: 32983280
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicines: The magic bullets reaching their target?
Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines: addressing the scientific and regulatory gap.
Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
[TBL] [Abstract][Full Text] [Related]
15. Regulatory aspects on nanomedicines.
Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
[TBL] [Abstract][Full Text] [Related]
16. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.
Hare JI; Lammers T; Ashford MB; Puri S; Storm G; Barry ST
Adv Drug Deliv Rev; 2017 Jan; 108():25-38. PubMed ID: 27137110
[TBL] [Abstract][Full Text] [Related]
17. Membrane-encapsulated camouflaged nanomedicines in drug delivery.
Ghosh S; Girigoswami K; Girigoswami A
Nanomedicine (Lond); 2019 Aug; 14(15):2067-2082. PubMed ID: 31355709
[TBL] [Abstract][Full Text] [Related]
18. Microfluidic Manufacture of Lipid-Based Nanomedicines.
Osouli-Bostanabad K; Puliga S; Serrano DR; Bucchi A; Halbert G; Lalatsa A
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145688
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicines: From Bench to Bedside and Beyond.
Havel H; Finch G; Strode P; Wolfgang M; Zale S; Bobe I; Youssoufian H; Peterson M; Liu M
AAPS J; 2016 Nov; 18(6):1373-1378. PubMed ID: 27480318
[TBL] [Abstract][Full Text] [Related]
20. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.
Haque S; Whittaker MR; McIntosh MP; Pouton CW; Kaminskas LM
Nanomedicine; 2016 Aug; 12(6):1703-24. PubMed ID: 27033834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
